E-news: Histone modifying enzymes as prostate carcinoma markers

Biomarkers are used to screen and characterise prostate carcinomas.

Vieira et al screened 37 histone methyltransferases (HMTs) and 20 histone demethylases (HDMs) in prostate cancer  samples. Changes in gene expression levels were found for several genes, of which 5 HMTs and 4 HDMs were investigated further in 150 prostate carcinoma samples.

The HMT PRMT6 discriminated between prostate carcinoma tissue and normal tissue with the highest sensitivity and specificity.

Increased expression levels of the HMT SMYD3 were associated with advanced disease, and may be useful as a predictor of disease progression.

The profiling of histone modifying enzymes, particularly SMYD3, may be useful in the clinical assessment of prostate cancers and aid therapeutic management of the disease.

Read more.